論文

査読有り
2016年11月

Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial

ANNALS OF ONCOLOGY
  • M. Ikeda
  • S. Shimizu
  • T. Sato
  • M. Morimoto
  • Y. Kojima
  • Y. Inaba
  • A. Hagihara
  • M. Kudo
  • S. Nakamori
  • S. Kaneko
  • R. Sugimoto
  • T. Tahara
  • T. Ohmura
  • K. Yasui
  • K. Sato
  • H. Ishii
  • J. Furuse
  • T. Okusaka
  • 全て表示

27
11
開始ページ
2090
終了ページ
2096
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1093/annonc/mdw323
出版者・発行元
OXFORD UNIV PRESS

Sorafenib (Sor) is acknowledged as a standard therapy for advanced hepatocellular carcinoma (HCC). This trial was conducted to evaluate the effect of addition of hepatic arterial infusion chemotherapy with cisplatin (SorCDDP) to Sor for the treatment of advanced HCC.
We conducted a multicenter open-labeled randomized phase II trial in chemo-na < ve patients with advanced HCC with Child-Pugh scores of 5-7. Eligible patients were randomly assigned 2:1 to receive SorCDDP (sorafenib: 400 mg bid; cisplatin: 65 mg/m(2), day 1, every 4-6 weeks) or Sor (400 mg bid). The primary end point was overall survival.
A total of 108 patients were randomized (Sor, n = 42; SorCDDP, n = 66). The median survival in the Sor and SorCDDP arms were 8.7 and 10.6 months, respectively [stratified hazard ratio (95% confidence interval), 0.60 (0.38-0.96), P = 0.031]. The median time to progression and the response rate were, respectively, 2.8 months and 7.3% in the Sor arm and 3.1 months and 21.7% in the SorCDDP arm. The adverse events were more frequent in the SorCDDP arm than in the Sor arm, but well-tolerated.
SorCDDP yielded favorable overall survival when compared with Sor in patients with advanced HCC.
UMIN-CTR (), identification number: UMIN000005703.

リンク情報
DOI
https://doi.org/10.1093/annonc/mdw323
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000388528900017&DestApp=WOS_CPL
ID情報
  • DOI : 10.1093/annonc/mdw323
  • ISSN : 0923-7534
  • eISSN : 1569-8041
  • Web of Science ID : WOS:000388528900017

エクスポート
BibTeX RIS